Fin Cascade
Get Android appGet iOS app

Prices as of 9 Oct 2026 close · Not investment advice

Medi Caps Limited

NSE: MEDICAPQPharmaceuticalsTrade-to-trade true

Share price

₹25.50

+4.98% close of 9 Oct 2026

Market cap ₹32 CrP/E —

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 5 Oct 2026, the close above is 9 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

29

out of 100 · worked out 9 Oct 2026

How the business score works

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹32 Cr

P/E ratio

—

P/B ratio

0.3

ROCE

-9.2%

ROE

-9.4%

Dividend yield

0.0%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 9 Oct 2026 close52-week high ₹40.4252-week low ₹21.86

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales fell 42.8% over the past year. Meanwhile what it keeps of every 100 rupees of sales slipped from 10.7% to -73.5% over the last four years.

Whether it grew faster than its sector

It grew -18.0% a year against a sector median of 13.1% — 31.0 percentage points slower.

Room to re-rate, or risk of de-rating

It has no earnings, so there is no price-to-earnings to compare.

Whether growth justifies the valuation

It has no earnings to weigh the price against.

Profit growthPrice per ₹1 profitPer 1% growth
Medi Caps Limited — this one———
Ind-Swift Laboratories Limited-6%/yr48.3×—
Solara Active Pharma Sciences Limited25%/yr——
Shukra Pharmaceuticals Limited—89.3×—
Hikal Limited-30%/yr63.0×—
Fredun Pharmaceuticals Limited—59.7×—

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 125 of 130 on returns, 126 of 127 on growth, 127 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

It is losing money on the capital in the business, so there is no advantage to measure.

Whether its growth pays for itself

Yes — Over the last five years it made ₹6 crore of cash from the business, spent ₹5 crore on plant and equipment, and returned ₹0 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 12 years, about 276 arrived as cash — well above the profit; depreciation and interest are the reason, not a windfall. Its cash comes back more slowly than it used to: it went from being waiting 87.7 days for its cash to waiting 598.1 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

4 of 7 checks clear · 57%

How the profit check works

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Announced 6 Aug 2026 · Consolidated · Unaudited

Revenue

₹3 Cr

Revenue vs last year

+3.6%

Revenue vs last quarter

-19.2%

Net profit

-₹2 Cr

Profit vs last quarter

-173.5%

Net margin

-80.1%

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹32 Cr
Prev close
₹25.50
52w High
₹44.7
52w Low
₹20.3
Enterprise value
₹31 Cr
Beta
0.7
Price CAGR 1y
-30.0%
Price CAGR 3y
-15.0%
Price CAGR 5y
-9.0%
Price CAGR 10y
1.0%

Ratios

Return on assets
-2.6%
PEG ratio
—
P/E ratio
—
P/B ratio
0.3
EV / EBITDA
—
Industry P/E
37.6
ROCE
-9.2%
ROCE 5y average
0.0%
ROE
-9.4%
Debt / Equity
0.0
Interest coverage
-150.5
Dividend yield
0.0%
ROE 3y average
-4.0%
ROE last year
-9.0%

Annual P&L

Annual revenue
₹12 Cr
Annual profit
-₹3 Cr
Operating margin
-75.6%
Net profit margin
-24.4%
EBITDA margin
-75.6%
Sales growth 3y
-36.8%
Sales growth 5y
-26.3%
Profit growth 3y
—
Profit growth 5y
—
EPS
₹-2.4
Sales growth TTM
-43.0%
Profit growth TTM
49.0%
Dividend payout
0.0%

Quarter P&L

Sales latest quarter
₹3 Cr
Profit latest quarter
-₹2 Cr
YoY quarterly sales growth
3.7%
YoY quarterly profit growth
—
OPM latest quarter
-65.6%

Balance Sheet

Book Value
₹89.5
Face Value
₹10.0
Total debt
₹0 Cr
Total cash
₹1 Cr
Borrowings
₹0 Cr
Reserves / Equity
8.0

Cash Flow

Operating cash flow
-₹7 Cr
Free cash flow
-₹8 Cr
FCF yield
-24.8%
Net cash flow
₹0 Cr

Shareholding

Promoter holding
51.4%
FII holding
—
DII holding
0.0%
Public holding
48.5%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,781.9033.94,27,5380.892,901.26.015,299.910.520.5
Divi's Lab.9,158.3081.62,43,1240.32902.065.53,080.027.822.0
Torrent Pharma.4,744.9080.91,80,4810.80566.05.84,921.054.915.2
Zydus Lifesci.1,141.0023.41,13,8150.09990.2-35.18,017.022.021.1
Cipla1,332.8530.11,07,6770.98785.6-39.27,119.32.315.5
Laurus Labs1,961.2096.91,05,9660.10362.1125.52,026.329.117.8
Mankind Pharma2,480.9048.11,02,4720.04574.129.64,030.612.913.5
Medi Caps24.75310.00-2.236.12.83.7-9.2
Median413.5034.32,1540.0613.229.6160.318.614.9

Competes with: Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales6.386.037.077.876.208.294.026.972.692.024.303.452.79
Expenses7.115.536.378.376.487.845.807.206.074.935.365.514.62
Material Cost1.40
Change in Inventories-0.12
Purchases of Stock-in-Trade0
Employee Cost1.91
Other Expenses1.42
Operating Profit-0.730.500.70-0.50-0.280.45-1.78-0.23-3.38-2.91-1.06-2.06-1.83
OPM %-118.299.90-6.35-4.525.43-44-3.30-126-144-25-60-66
Other Income0.070.070.090.240.150.290.162.140.331.530.765.590.05
Exceptional items (within Other Income)0
Interest00000000.020.010000
Depreciation0.450.450.450.330.430.430.430.440.440.440.440.500.45
Profit before tax-1.110.120.34-0.59-0.560.31-2.051.45-3.50-1.82-0.743.03-2.23
Tax %0015083000-19004.05-0.330
Net Profit-1.110.12-0.16-1.08-0.560.31-2.051.72-3.49-1.82-0.773.04-2.23
EPS in Rs-0.890.10-0.13-0.87-0.450.25-1.641.38-2.80-1.46-0.622.44-1.79

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales36434454524357704927251213
Expenses36404252475046604427272220
Operating Profit-0.082.611.612.174.72-6.7511105.190-1.80-9.41-7.86
OPM %-0.226.073.664.049.11-161914110-7.06-76-63
Other Income1.290.682.021.072.732.861.771.951.490.482.738.217.93
Interest0.660.060.100.100.130.120.100.110.130.040.050.020
Depreciation1.811.801.811.791.821.831.521.811.741.691.721.811.83
Profit before tax-1.261.431.721.355.50-5.8411104.81-1.25-0.84-3.03-1.76
Tax %633920152.180.17-0.090.106480-320.66
Net Profit-2.060.861.371.155.39-5.8511101.76-2.24-0.57-3.04-1.78
EPS in Rs-1.650.691.100.924.32-4.698.938.081.41-1.80-0.46-2.44-1.43
Dividend Payout %000000000000

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
-12%
5 years
-26%
3 years
-37%
TTM
-43%

Compounded profit growth

10 years
—
5 years
—
3 years
—
TTM
49%

Stock price CAGR

10 years
1%
5 years
-9%
3 years
-15%
1 year
-30%

Return on equity

10 years
1%
5 years
-1%
3 years
-4%
Last year
-9%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital121212121212121212121212
Reserves6970777883789210410610910999
Borrowings0.810.080.090.170.120.06000000
Other Liabilities7118.1911114.2010147.426.314.143.85
Total Liabilities89939710110795115130126127125115
Fixed Assets585662616057585959595756
CWIP000000.970.540.24000.080
Investments5.436.747.83111622293132384335
Other Assets263027293015274035302524
Total Assets89939710110795115130126127125115

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity7.052.594.024.205.964.63157.02-6.086.945.07-7.02
Cash from Investing Activity-6.97-1.472.57-4.09-5.75-5.80-9.70-4.08-2.56-7.73-4.987.11
Cash from Financing Activity0-0.73-5.760.08-0.05-0.06-0.0600000
Net Cash Flow0.080.390.830.200.16-1.235.562.95-8.64-0.790.090.09
Free Cash Flow6.582.439.113.515.373.38134.23-7.246.594.74-7.87

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days878274899137415363144126203
Inventory Days2662572301481647583157122243121210
Days Payable66102769196277715449776034
Cash Conversion Cycle287238229146158864755136310187378
Working Capital Days184154147113127856588201324304598
ROCE %-0.691.811.481.565.77-6.58128.783.70-1.17-2.12-9.19

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters505050505051515151515151
DIIs0.030.030.030.030.030.030.030.030.030.020.020.02
Public505050505049494949494949
No. of Shareholders13,79013,22612,35611,73811,25511,17611,03310,85110,69210,49310,34910,209

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year -33.8% (₹38.50 → ₹25.50)Brick size ₹1.84 (fixed)Bricks 31
₹30.00₹35.00₹40.00₹25.50Nov '25Jan '26Apr '26Jun '26Aug '26
Price moved up one brickPrice moved down one brickLast close ₹25.50 on 9 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

-0.50inr_cr

2026-03-31

News

News and filings about Medi Caps Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE442D01010

News impact

Big market events that reach Medi Caps Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

No dividends, splits or big trades on record.

Documents

Annual reports, results presentations and earnings calls, straight from the source.

No documents on record yet.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.